Inhibitors of Cytochrome P-450s and Their Mechanism of Action

References

• Testa B., Jenner P. Drug Metabolism; Chemical and Biochemical Aspects. Marcel Dekker, New York 1976; 357–358
   Google Scholar
• Ullrich V., Roots I., Hildebrandt A., Estabrook R. W., Conney A. H. Microsomes and Drug Oxidation. Pergamon, Oxford 1977
   Google Scholar
• Microsomes, Drug Oxidations, and Chemical Carcinogenesis, M. J. Coon, A. H. Conney, R. W. Estabrook, H. V. Gelboin, J. R. Gillette, P. J. O'Brien. Academic, New York 1980; vols. 1, 2
   Google Scholar
• Palmer E. D., Cawthorne M. A. “The effects of 1-alkyl-imidazoles on hepatic drug-metabolizing enzyme activity”. Xenobiotica 1974; 4: 209–217
   PubMed Web of Science ®Google Scholar
• Pannatier A., Testa B., Etter J. C. Effect of topically applied phenobarbital on mouse skin O-dealkylase activity and cytochrome P-450, in preparation.
   Google Scholar
• Cinti D. L. Agents activating the liver microsomal mixed function oxidase system. Pharmacol. Ther. A. 1978; 2: 727–749
   Web of Science ®Google Scholar
• Mannering G. J. Hepatic cytochrome P-450-linked drug-metabolizing systems. Concepts in Drug Metabolism, P. Jenner, B. Testa. Marcel Dekker, New York 1981; 53–166, part B
   Google Scholar
• Traylor T. G., Mincey T. “Mercaptide chelated proto-heme: A model compound for cytochrome P-450”. Acta Biol. Med. Germ. 1979; 38: 351–355
   PubMedGoogle Scholar
• Collman J. P., Sorrell T. N. “A model for the carbonyl adduct of ferrous cytochrome P-450”. J. Amer. Chem. Soc. 1975; 97: 4133–4134
   PubMed Web of Science ®Google Scholar
• Jung C., Friedrich J., Ristau O. Quantum chemical interpretation of the spectral properties of the CO and O2 complexes of hemoglobin and cytochrome P-450. Acta Biol. Med. Germ. 1979; 38: 363–377
   PubMedGoogle Scholar
• Collman J. P., Brauman J. I., Halbert T. R., Suslick K. S. Nature of O2 and CO binding to metalloporphyrins and heme proteins. Proc. Nat. Acad. Sci. U.S. 1976; 73: 3333–3337
   PubMed Web of Science ®Google Scholar
• Gorrod J. W. On the multiplicity of microsomal N-oxidase systems. Mechanism of Oxidizing Enzymes, T. P. Singer, R. N. Ondarza. Elsevier, New York 1978; 189–197
   Google Scholar
• Conney A. H., Levin W., Ikeda M., Kuntzman R., Cooper D. Y., Rosenthal O. “Inhibitory effect of carbon monoxide on the hydroxylation of testosterone by rat liver microsomes”. J. Biol. Chem. 1968; 243: 3912–3915
   PubMed Web of Science ®Google Scholar
• Canick J. A., Ryan K. J. “Cytochrome P-450 and the aromatization of 16a-hydroxytestosterone and androstenedione by human placental microsomes”. Mol. Cell. Endocrinol. 1976; 6: 105–115
   PubMed Web of Science ®Google Scholar
• Sugiura M., Iwasaki K., Kato R. “Reduced nicotinamide adenine dinucleotide-dependent reduction of tertiary amine N-oxide by liver microsomal cytochrome P-450”. Biochem. Pharmacol. 1977; 26: 489–495
   PubMed Web of Science ®Google Scholar
• Nambara S., Yamaha T. “Comparison of bacterial and microsomal azo- and nitro-reductases”. J. Pharm. Soc. Jap. 1975; 95: 1302–1306
   PubMed Web of Science ®Google Scholar
• Ullrich V. The mechanism of cytochrome P-450 action. 192–201, In ref. 2
   Google Scholar
• Pirrwitz J., Rein H., Lassmann G., Jänig G. R., Pečar S., Ruckpaul K. “Spin-labelled isocyanides as stereochemical probes for the active center of cytochrome P-450”. FEBS Lett. 1979; 101: 195–200
   PubMed Web of Science ®Google Scholar
• Werringloer J., Estabrook R. W. “Heterogeneity of liver microsomal cytochrome P-450: The spectral characterization of reactants with reduced cytochrome P-450”. Arch. Biochem. Biophys. 1975; 167: 270–286
   PubMed Web of Science ®Google Scholar
• Imai Y., Sato R. “Dual effect of ethyl isocyanide on drug hydroxylation by liver microsomes”. J. Biochem. 1968; 63: 380–389
   PubMed Web of Science ®Google Scholar
• Imai Y., Sato R. “Activation and inhibition of microsomal hydroxylation by ethyl isocyanide”. Biochem. Biophys. Res. Commun. 1966; 25: 80–86
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Kumaki K., Sato M., Kon H. Association of type I, type II, and reverse type I difference spectra with absolute spin state of cytochrome P-450 iron. 224–231, in Ref, 2
   Google Scholar
• Kitada M., Chiba K., Kamataki T., Kitagawa H. “Inhibition by cyanide of drug oxidations in rat liver microsomes”. Jap. J. Pharmacol. 1977; 27: 601–608
   PubMedGoogle Scholar
• Ho B., Castagnoli N., Jr. Trapping of metabolically generated electrophilic species with cyanide ion: Metabolism of 1-benzylpyrrolidine. J. Med. Chem. 1980; 23: 133–139
   PubMed Web of Science ®Google Scholar
• Shertzer H. G., Duthu G. S. Nitrite binding to rabbit liver microsomes and effects on aminopyrine demethylation. Biochem. Pharmacol. 1979; 28: 873–879
   PubMed Web of Science ®Google Scholar
• Duthu G. S., Shertzer H. G. “Effect of nitrite on rabbit liver mixed-function oxidase activity”. Drug. Metab. Dispos. 1979; 7: 263–269
   PubMed Web of Science ®Google Scholar
• Kahl R., Wulff U., Netter K. J. “Effect of nitrite on microsomal cytochrome P-450”. Xenobiotica 1978; 8: 359–364
   PubMed Web of Science ®Google Scholar
• Kumaki K., Nebert D. W. “Spectral evidence for weak lig-and in sixth position of hepatic microsomal cytochrome P-450 low spin ferric ion in vivo”. Pharmacology 1978; 17: 262–279
   PubMed Web of Science ®Google Scholar
• Ruf H. H., Wende P., Ullrich V. “Models for ferric cytochrome P-450 characterization of hemin mercaptide complexes by electronic and ESR spectra”. J. Inorg. Biochem. 1979; 11: 189–204
   PubMed Web of Science ®Google Scholar
• Khanna J. M., Kalant H., Yee Y., Chung S., Siemens A. J. “Effect of chronic ethanol treatment on metabolism of drugs in vivo and in vitro”. Biochem. Pharmacol. 1976; 25: 329–335
   PubMed Web of Science ®Google Scholar
• Hultmark D., Sundh K., Johansson L., Arrhenius E. Dichloro-p-nitroanisole O-demethylase, II: Evidence for separate ethanol inhibited and phenobarbital-inducible enzymes. Biochem. Pharmacol. 1979; 28: 1587–1590
   PubMed Web of Science ®Google Scholar
• Hultmark D., Sundh K., Johansson L., Arrhenius E. “Ethanol inhibition of vinyl chloride metabolism in isolated rat hepatocytes”. Chem.-Biol. Interact. 1979; 25: 1–6
   PubMed Web of Science ®Google Scholar
• Wollenberg P., Ullrich V. Characterization of the drug monooxygenase system in mouse small intestine. 675–679, in Ref. 2
   Google Scholar
• Cohen G. M., Mannering G. J. “Involvement of a hydrophobic site in the inhibition of the microsomal para-hydroxyla-tion of aniline by alcohols”. Molec. Pharmacol. 1973; 8: 383–397
   Google Scholar
• Testa B. Structural and electronic factors influencing the inhibition of aniline hydroxylation by alcohols and their binding to cytochrome P-450. Chem.-Biol. Interact. 1981; 34: 287–300
   PubMed Web of Science ®Google Scholar
• Nagata C., Fujita H., Imamura I. “A molecular orbital study on the interaction between the cytochrome P-450 and its substrates”. Chem.-Biol. Interact. 1976; 12: 1–12
   PubMed Web of Science ®Google Scholar
• Schichi H., Kumaki K., Nebert D. W. “Circular dichroism studies on the binding of type I substrate and reverse type I compounds to rabbit liver microsomal cytochrome P-450”. Chem.-Biol. Interact. 1978; 20: 133–148
   PubMed Web of Science ®Google Scholar
• Ullrich V., Kremers P. “Multiple forms of cytochrome P-450 in the microsomal monooxygenase system”. Arch. Toxicol. 1977; 39: 41–50
   PubMed Web of Science ®Google Scholar
• Shimada T., Sato R. Inhibition of monooxygenase activities by 1,1,1-trichloropropene 2,3-oxide, an inhibitor of epoxide hydrase, in rat liver microsomes. Biochem. Pharmacol. 1979; 28: 1777–1781
   PubMed Web of Science ®Google Scholar
• Wilson D. W., Hansen L. G. “Comparative kinetics and inhibition of swine and sheep liver microsomal enzymes”. Gen. Pharmacol. 1976; 7: 371–375
   PubMedGoogle Scholar
• Wattenberg L. W., Lam L. K. T., Fladmoe A. V. “Inhibition of chemical carcinogen-induced neoplasia by cou-marins and a-angelicalactone”. Cancer Res. 1979; 39: 1651–1654
   PubMed Web of Science ®Google Scholar
• Kramer R. E., Greiner J. W., Rumbaugh R. C., Sweeney T. D., Colby H. D. “Requirement of the pituitary gland for gonadal hormone effects on hepatic drug metabolism in rats”. J. Pharmacol. Exp. Ther. 1979; 208: 19–23
   PubMed Web of Science ®Google Scholar
• Orrenius S., Moldeus P., Thor H., Hogberg J. The physiological implications of drug oxidations to the cell. 292–306, in Ref. 2
   Google Scholar
• Rahimtula A. D., O'Brien P. J. The peroxidase nature of cytochrome P-450. 210–217, in Ref. 2
   Google Scholar
• DiGiovanni J., Slaga T. J., Berry D. L., Juchau M. R. Metabolism of 7,12-dimethylbenz[a]anthracene in mouse skin homogenates analyzed with HPLC. Drug Metab. Dispos. 1977; 5: 295–301
   PubMed Web of Science ®Google Scholar
• Soda D. M., Levy G. “Inhibition of drug metabolism by hydroxylated metabolites: Cross-inhibition and specificity”. J. Pharm. Sci. 1975; 64: 1928–1931
   PubMed Web of Science ®Google Scholar
• Thakker D. R., Levin W., Yagi H., Ryan D., Thomas P. E., Karle J. M., Lehr R. E., Jerina D. M., Conney A. H. Metabolism of benzo[a]anthracene to its tumorigenic 3,4-di-hydrodiol. Molec. Pharmacol. 1979; 15: 138–153
   PubMed Web of Science ®Google Scholar
• Bobik A., Holder G. M., Ryan A. J. Inhibitors of hepatic mixed function oxidases, 111: Inhibition of hepatic microsomal aniline hydroxylase and aminopyrine demethylase by 2, 6- and 2,4-dihydroxyphenyl aryl ketones and related compounds. J. Med. Chem. 1977; 20: 1194–1199
   PubMed Web of Science ®Google Scholar
• Yang C. S., Strickhart F. S. “Inhibition of hepatic mixed function oxidase activity by propyl gal late”. Biochem. Pharmacol. 1974; 23: 3129–3138
   PubMed Web of Science ®Google Scholar
• Yang C. S., Strickhart F. S., Woo G. K. “Inhibition of the mono-oxygenase system by butylated hydroxyanisole and butyl-ated hydroxytoluene”. Life Sci. 1974; 15: 1497–1505
   PubMed Web of Science ®Google Scholar
• Rahimtula A. D., O'Brien P. J., Zachariah P. K. “Effect of antioxidants on human placental aryl hydrocarbon hydroxylase”. Cancer Biochem. Biophys. 1979; 4: 9–11
   PubMedGoogle Scholar
• Netter K. J., Kahl R., Elcombe C. R. Significance of induction phenomena. Arch. Toxicol., Suppl. 1 1978; 85–99
   Google Scholar
• Shen A. L., Fahl W. E., Wrighton S. A., Jefcoate C. R. Inhibition of benzo[a]pyrene and benzo[a]pyrene 7, 8-dihydrodiol metabolism by benzo[a]pyrene quinones. Cancer Res. 1979; 39: 4123–4129
   PubMed Web of Science ®Google Scholar
• Mailman R. B., Kulkarni A. P., Baker R. C., Hodgson E. “Cytochrome P-450 difference spectra: Effect of chemical structure on type II spectra in mouse hepatic microsomes”. Drug Metab. Dispos. 1974; 2: 301–308
   PubMed Web of Science ®Google Scholar
• Jonen H. G., Hiithwohl B., Kahl R., Kahl G. F. “Influence of pyridine and some pyridine derivatives on spectral properties of reduced microsomes and on microsomal drug metabolizing activity”. Biochem. Pharmacol. 1974; 23: 1319–1329
   PubMed Web of Science ®Google Scholar
• Mull R., Hinkelbein W., Gertz J., Flemming K. A preliminary comparative study on the influence of cysteamine and metyrapone on mixed-function oxydase activities in variously pretreated liver microsomes from rats and mice. 354–361, in Ref. 2
   Google Scholar
• Born J. L., Early S. “Ligand interaction of substituted pyridines with cytochrome P-450”. J. Pharm. Sci. 1980; 69: 850–851
   PubMed Web of Science ®Google Scholar
• Kahl R, Bücker M., Netter K. J. Sex differences in the pattern of cytochromes P-450 in rat liver microsomes. 177–184, in Ref. 2
   Google Scholar
• Bücker M., Golan M., Schmassmann H. U., Glatt H. R., Stasiecki P., Oesch F. “The epoxide hydratase inducer trans-stilbene oxide shifts the metabolic epoxidation of benzo[a]pyrene from the bay- to the K-region and reduces its mutagenicity”. Molec. Pharmacol. 1979; 16: 656–666
   PubMed Web of Science ®Google Scholar
• Capdevila J., Estabrook R. W., Prough R. A. The ex-istance of a benzo[a]pyrene 3,6-quinone reductase in rat liver microsomal fractions. Biochem. Biophys. Res. Commun. 1978; 83: 1291–1298
   PubMed Web of Science ®Google Scholar
• Hodgson E., Juchau M. R. “Ligand binding to human placental cytochrome P-450: Interaction of steroids and heme-binding ligands”. J. Steroid Biochem. 1977; 8: 669–675
   PubMedGoogle Scholar
• Napoli J. L., Counsell R. E. New inhibitors of steroid 11β -hydroxylase, Structure-activity relationship studies of metyrapone-like compounds. J. Med. Chem. 1977; 20: 762–766
   PubMed Web of Science ®Google Scholar
• Gregotti C., Rugarli P. L., Di Nucci A., Richelmi P., Manzo L., Berte F. “Inhibition of hepatic microsomal monooxygenase activity by oxine-5-sulfonic acid administered orally in rabbits”. Farmaco Ed. Prat. 1979; 34: 474–477
   PubMedGoogle Scholar
• Mannering G. J. Microsomal enzyme systems which catalyze drug metabolism. Fundamentals of Drug Metabolism and Drug Disposition, B. N. La Du, H. G. Mandel, E. L. Way. Williams & Wilkins, Baltimore 1971; 206–252
   Google Scholar
• Leibmann K. C., Ortiz E. “Metyrapone and other modifiers of microsomal drug metabolism”. Drug Metab. Dispos. 1973; 1: 184–189
   PubMed Web of Science ®Google Scholar
• Wilkinson C. F., Hetnarski K., Yellin T. O. “Imidazole derivatives: A new class of microsomal enzyme inhibitors”. Biochem. Pharmacol. 1972; 21: 3187–3192
   PubMed Web of Science ®Google Scholar
• Wilkinson C. F., Hetnarski K., Hicks L. J. “Substituted imidazoles as inhibitors of microsomal oxidation and insecticide synergists”. Pestic. Biochem. Physiol. 1974; 4: 299–312
   Web of Science ®Google Scholar
• Bolt H. M., Kassel H. “Effect of insecticide synergists on microsomal oxidation of estradiol and ethynylestradiol and on microsomal drug metabolism”. Xenobiotica 1976; 6: 33–38
   PubMed Web of Science ®Google Scholar
• Wilkinson C. F., Hetnarski K., Cantwell G. P., DiCarlo F. J. “Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo”. Biochem. Pharmacol. 1974; 23: 2377–2386
   PubMed Web of Science ®Google Scholar
• Smith L. R., Wilkinson C. F. “Inhibition of microsomal oxidation by some bis(imidazolyl) derivatives”. Biochem. Pharmacol. 1978; 27: 1383–1384
   PubMed Web of Science ®Google Scholar
• Dickins M., Elcombe C. R., Nimmo-Smith R. H., Bridges J. W. “Structure-binding relationships between benzimid-azoles and cytochrome P-450”. Biochem. Soc. Trans. 1975; 3: 970–972
   Web of Science ®Google Scholar
• Razzouk C., Agazzi-Leonard E., Cumps J., Poncelet F., Mercier M., Roberfroid M. Induction, modification, and inhibition of rat liver microsomal benzo[a]pyrene hydroxylase; correlation with the S-9-mediated mutagenicity of benzo[a]pyrene. Biochem. Biophys. Res. Commun. 1978; 85: 1007–1016
   PubMed Web of Science ®Google Scholar
• Smith L. R., Wilkinson C. F. Influence of steric factors on the interaction of isomeric phenyloxazoles and phenyl-thiazoles with microsomal oxidation. Biochem. Pharmacol. 1978; 27: 2466–2467
   PubMed Web of Science ®Google Scholar
• Lesca P., Lecointe P., Paoletti C., Mansuy D. “Ellipti-cines as potent inhibitors of drug metabolism: Protective effect against chemical mutagenesis and carcinogenesis”. Biochimie 1978; 60: 1011–1068
   Web of Science ®Google Scholar
• Lesca P., Rafidinarivo E., Lecointe P., Mansuy D. “A class of strong inhibitors of microsomal monooxygenases: The ellipticines”. Chem.-Biol. Interact. 1979; 24: 189–198
   PubMed Web of Science ®Google Scholar
• Guenthner T. M., Kahl G. F., Nebert D. W. “NADPH-cytochrome P-450 reductase: Preferential inhibition by ellipticines and other type II compounds having little effect on NADPH-cytochrome c reductase”. Biochem. Pharmacol. 1980; 29: 89–95
   PubMed Web of Science ®Google Scholar
• Goujon F. M., Nebert D. W., Gielen J. E. Genetic expression of aryl hydrocarbon hydroxylase induction, IV: Interaction of various compounds with different forms of cytochrome P-450 and the effect on benzo[a]pyrene metabolism in vitro. Molec. Pharmacol. 1972; 8: 667–680
   PubMed Web of Science ®Google Scholar
• Kapitulnik J., Poppers P. J., Buening M. K., Fortner J. G., Conney A. H. Activation of monooxygenases in human liver by 7, 8-benzoflavone. Clin. Pharmacol. Ther. 1977; 22: 475–485
   PubMed Web of Science ®Google Scholar
• Burke M. D., Prough R. A., Mayer R. T. “Characteristics of a microsomal cytochrome P-448-mediated reaction: Ethoxyresorufin O-deethylation”. Drug Metab. Dispos. 1977; 5: 1–8
   PubMed Web of Science ®Google Scholar
• Thorgeirsson S. S., Atlas S. A., Boobis A. R., Felton J. S. “Species differences in the substrate specificity of hepatic cytochrome P-448 from polycyclic hydrocarbon-treated animals”. Biochem. Pharmacol. 1979; 28: 217–226
   PubMed Web of Science ®Google Scholar
• Johnson E. F., Schwab G. E., Muller-Eberhard U. “Multiple forms of cytochrome P-450: Catalytic differences exhibited by two homogenous forms of rabbit cytochrome P-450”. Molec. Pharmacol. 1979; 15: 708–718
   PubMed Web of Science ®Google Scholar
• Jellinck P. H., Smith G., Newcombe A.-M. Inhibition of hepatic aryl hydrocarbon hydroxylase by 3-methylcholan-threne, 7, 8-benzoflavone, and other inducers added in vitro. Chem.-Biol. Interact. 1975; 11: 459–468
   PubMed Web of Science ®Google Scholar
• Nesnow S. A preliminary structure-activity study of the mixed-function oxidase inhibitor 7, 8-benzoflavone. J. Med. Chem. 1979; 22: 1244–1247
   PubMed Web of Science ®Google Scholar
• Franklin M. R. “Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes”. Pharmacol. Ther. A 1977; 2: 227–245
   Web of Science ®Google Scholar
• Hodgson E., Philpot R. M. Interaction of methylenedioxy-phenyl (1,3-benzodioxole) compounds with enzymes and their effects on mammals. Drug. Metab. Rev. 1974; 3: 231–301
   PubMed Web of Science ®Google Scholar
• Fujii K., Jaffe H., Bishop Y., Arnold E., Mackintosh D., Epstein S. S. Structure-activity relations for methylene-dioxyphenyl and related compounds on hepatic microsomal enzyme function, as measured by prolongation of hexobarbital narcosis and zoxazolamine paralysis in mice. Toxicol. Appl. Pharmacol. 1970; 16: 482–494
   PubMed Web of Science ®Google Scholar
• Dickins M., Bridges J. W., Elcombe C. R., Netter K. J. “A novel haemoprotein induced by isosafrole pretreatment in the rat”. Biochem. Biophys. Res. Commun. 1978; 80: 89–96
   PubMed Web of Science ®Google Scholar
• Friedman M. A., Woods S. “Effects of piperonyl butoxide on hydroxylation of 2-acetylaminofluorene in mouse liver”. Res. Commun. Chem. Pathol. Pharmacol. 1977; 17: 623–630
   PubMedGoogle Scholar
• Ullrich V., Schnabel K. H. “Formation and binding of carbanions by cytochrome P-450 of liver microsomes”. Drug Metab. Dispos. 1973; 1: 176–183
   PubMed Web of Science ®Google Scholar
• Mansuy D. Activation des composés organiques exogènes par les cytochromes P-450: Implications en pharmacologic et en toxicologic. Mises au Point de Biochimie Pharmacologique, G. Siest, C. Heusghem. Masson, Paris 1979; 123–146, 2nd series
   Google Scholar
• Netter K. J., Kahl R., Elcombe C. R. Significance of induction phenomena. Arch. Toxicol., Suppl. 1 1978; 85–99
   Google Scholar
• Fennell T. R., Dickins M., Bridges J. W. “Interaction of isosafrole in vivo with rat hepatic microsomal cytochrome P-450 following treatment with phenobarbitone or 20-methyl-cholanthrene”. Biochem. Pharmacol. 1979; 28: 1427–1429
   PubMed Web of Science ®Google Scholar
• Dahl A. R., Hodgson E. “The interaction of aliphatic analogs of methylenedioxyphenyl compounds with cytochromes P-450 and P-420”. Chem.-Biol. Interact. 1979; 27: 163–175
   PubMed Web of Science ®Google Scholar
• Gorrod J. W., Damani L. A. The effects of various potential inhibitors, activators, and inducers on the N-oxidation of 3-substituted pyridines in vitro. Xenobiotica 1979; 9: 219–226
   PubMed Web of Science ®Google Scholar
• Testa B., Jenner P. “Novel drug metabolites produced by functionalization reactions: Chemistry and toxicology”. Drug Metab. Rev. 1978; 7: 325–369
   PubMed Web of Science ®Google Scholar
• Schenkman J. B., Wilson B. J., Cinti D. L. Diethylaminoethyl 2,2-diphenylvalerate HC1 (SKF-525A). In vivo and in vitro effects of metabolism by rat liver microsomes–formation of an oxygenated complex. Biochem. Pharmacol. 1972; 21: 2373–2383
   PubMed Web of Science ®Google Scholar
• Jonsson J., Lindeke B. On the formation of cytochrome P-450 product complexes during the metabolism of phenyl-alkylamines. Acta Pharm. Suec. 1976; 13: 313–320
   PubMedGoogle Scholar
• Hirata M., Lindeke B., Orrenius S. “Cytochrome P-450 product complexes and glutathione consumption produced in isolated hepatocytes by norbenzphetamine and its N-oxidized congeners”. Biochem. Pharmacol. 1979; 28: 479–484
   PubMed Web of Science ®Google Scholar
• Mansuy D., Beaune P., Chottard J. C., Bartoli J. F., Gans P. “The nature of the “455 nm absorbing complex” found during the cytochrome P-450 dependent oxidative metabolism of amphetamine”. Biochem. Pharmacol. 1976; 25: 609–612
   PubMed Web of Science ®Google Scholar
• Mansuy D. Coordination chemistry of cytochromes P-450 and iron-porphyrins: Relevance to pharmacology and toxicology. Biochimie 1978; 60: 969–977
   Web of Science ®Google Scholar
• Franklin M. R. The inhibition of mixed-function oxidation reactions by amphetamines in liver and lung microsomes. 284–291, in Ref. 2
   Google Scholar
• Gal J., Wright J., Cho A. K. “In vitro metabolism of amphetamine: An apparent enantiomeric interaction”. Res. Commun. Chem. Pathol. Pharmacol. 1976; 15: 525–540
   PubMedGoogle Scholar
• Vree T. B., Henderson P. T., van Rossum J. M., Doukas P. H. “In vivo and in vitro inhibition of the metabolism of N-alkyl-substituted amphetamines in rat by ferrocenyliso-propylamine”. Xenobiotica 1973; 3: 23–35
   PubMed Web of Science ®Google Scholar
• Mansuy D., Rouer E., Bacot C., Gans P., Chottard J. C., Leroux J. P. “Interaction of aliphatic hydroxylamines with microsomal cytochrome P-450: Nature of the different derived complexes and inhibitory effects on monooxygenases activities”. Biochem. Pharmacol. 1978; 21: 1229–1237
   Google Scholar
• Coutts R. T., Beckett A. H. “Metabolic N-oxidation of primary and secondary aliphatic medicinal amines”. Drug Metab. Rev. 1977; 6: 51–104
   Web of Science ®Google Scholar
• Gumbrecht J. R., Franklin M. R. The formation of cytochrome P-450-metabolic intermediate complexes from amines, in the isolated perfused rat liver. Xenobiotica 1979; 9: 547–554
   PubMed Web of Science ®Google Scholar
• Jenner S., Netter K. J. “On the inhibition of microsomal drug metabolism by SKF-525A”. Biochem. Pharmacol. 1972; 21: 1921–1927
   PubMed Web of Science ®Google Scholar
• Gillette J. R. “Factors affecting drug metabolism”. Ann. N.Y. Acad. Sci. 1971; 179: 43–66
   PubMed Web of Science ®Google Scholar
• Conney A. H., Levin W., Jacobson M., Kuntzman R. “Effects of drugs and environmental chemicals on steroid metabolism”. Clin. Pharmacol. Ther. 1973; 14: 727–741
   PubMed Web of Science ®Google Scholar
• Buening M. K., Franklin M. R. SKF-525A inhibition, induction, and 452 nm complex formation. Drug Metab. Dispos. 1976; 4: 244–255
   PubMed Web of Science ®Google Scholar
• Fernandez G., Villarruel M. C., Castro J. A. Mechanism of the drug-metabolizing enzymes induction by 2-di-ethylamino-2,2-diphenylvalerate HC1 (SKF-525A). Toxicol. Appl. Pharmacol. 1978; 46: 315–321
   PubMed Web of Science ®Google Scholar
• Franklin M. R. A new class of inhibitory cytochrome P-450 complexes formed during metabolism: A comparison with amphetamine and SKF-525A type complexes. Chem.-Biol. Interact. 1976; U: 337–346
   Google Scholar
• Bast A., Noordhoek J. Inhibition of aminopyrine de-methylation and binding to cytochrome P-450 by its main metabolites in rat liver microsomes. Brit. J. Pharmacol. 1980; 68: 121P–122P
   PubMed Web of Science ®Google Scholar
• Mansuy D., Beaune P., Cresteil T., Bacot C., Chottard J. C., Gans P. “Formation of complexes between microsomal cytochrome P-450-Fe(II) and nitrosoarenes obtained by oxidation of arylhydroxylamines or reduction of nitroarenes in situ”. Eur. J. Biochem. 1978; 86: 573–579
   PubMedGoogle Scholar
• Sternson L. A., Gammans R. E. “Effect of aromatic nitro compounds on oxidative metabolism by cytochrome P-450 dependent enzymes”. J. Med. Chem. 1976; 19: 174–177
   PubMed Web of Science ®Google Scholar
• Hlavica P., Aichinger G. Studies on the cytochrome P-450 product complexes formed during the metabolism of N, N-dimethylaniline. Biochim. Biophys. Acta 1978; 544: 185–199
   PubMed Web of Science ®Google Scholar
• Appel K. E., Ruf H. H., Mahr B., Schwarz M., Rickart R., Kunz W. “Binding of nitrosamines to cytochrome P-450 of liver microsomes”. Chem.-Biol. Interact. 1979; 28: 17–33
   PubMed Web of Science ®Google Scholar
• Norred W. P., Nishie K., Keyl A. C. “Effects of short-term administration of nitrosamines on rat hepatic microsomal enzymes”. Biochem. Pharmacol. 1975; 24: 1313–1316
   PubMed Web of Science ®Google Scholar
• Kato R., Takanaka A., Shoji H. “Inhibition of drug-metabolizing enzymes of liver microsomes by hydrazine derivatives in relation to their lipid solubility”. Jap. J. Phar-macol. 1969; 19: 315–322
   PubMedGoogle Scholar
• Prough R. A., Coomes M. L., Dunn D. L. The microsomal metabolism of carcinogenic and/or therapeutic hydrazines. 500–507, in Ref. 2
   Google Scholar
• Hines R. N., Prough R. A. The characterization of an inhibitory complex formed with cytochrome P-450 and a metabolite of 1,1-disubstituted hydrazines. J. Pharmacol. Exp. Ther. 1980; 214: 80–86
   PubMed Web of Science ®Google Scholar
• Netter K. J. “Inhibition of oxidative drug metabolism in microsomes”. Pharmacol. Ther. 1980; 10: 515–535
   PubMed Web of Science ®Google Scholar
• Vainio H., Parkki M. G., Marniemi J. “Effects of aliphatic chlorohydrocarbons on drug-metabolizing enzymes in rat liver in vivo”. Xenobiotica 1976; 6: 599–604
   PubMed Web of Science ®Google Scholar
• Davis D. C., Schroeder D. H., Gram T. E., Reagan R. L., Gillette J. R. “A comparison of the effects of halothane and CCI4 on the hepatic drug metabolizing system”. J. Pharmacol. Exp. Ther. 1971; 177: 556–566
   PubMed Web of Science ®Google Scholar
• Koivusaari U., Lang M., Hietanen E. Differences in the response of hepatic and intestinal drug metabolizing enzymes in rats following carbon tetrachloride and/or phenobarbital treatment. Acta Pharmacol. Toxicol. 1980; 46: 37–42
   PubMedGoogle Scholar
• de Toranzo E. G. D., Diaz Gomez M. I., Castro J. A. “Mechanism of in vivo carbon tetrachloride-induced liver microsomal cytochrome P-450 destruction”. Biochem. Biophys. Res. Commun. 1975; 64: 823–828
   PubMed Web of Science ®Google Scholar
• Yamazoe Y., Sugiura M., Kamataki T., Kato R. “The apparent loss of cytochrome P-450 associated with metabolic activation of carbon tetrachloride”. Jap. J. Pharmacol. 1979; 29: 715–721
   PubMedGoogle Scholar
• Calligaro A., Vannini V. “Electron spin resonance study of homolytic cleavage of carbon tetrachloride in rat liver: Pentadienyl free radicals”. Pharmacol. Res. Commun. 1978; 10: 43–52
   PubMedGoogle Scholar
• Guzelian P. S., Swisher R. W. “Degradation of cytochrome P-450 haem by carbon tetrachloride and 2-allyl-2-isopropylacetamide in rat liver in vivo and in vitro: Involvement of non-carbon monoxide-forming mechanisms”. Biochem. J. 1979; 184: 481–489
   PubMed Web of Science ®Google Scholar
• De Groot H., Haas W. O2-Independent damage of eyto-cyrome P-450 by CCI4-metabolites in hepatic microsomes. FEBSLett. 1980; 115: 253–256
   PubMed Web of Science ®Google Scholar
• Wolf C. R., Mansuy D., Nastainczyk W., Deutschmann G., Ullrich V. “The reduction of polyhalogenated methanes by liver microsomal cytochrome P-450”. Mol. Pharmacol. 1977; 13: 698–705
   PubMed Web of Science ®Google Scholar
• Mansuy D., Fontecave M., Chottard J. C. “A heme model study of carbon tetrachloride metabolism: Mechanisms of phosgene and carbon dioxide formation”. Biochem. Biophys. Res. Commun. 1980; 95: 1536–1542
   PubMed Web of Science ®Google Scholar
• Sipes I. G., Krishna G., Gillette J. R. Bioactivation of carbon tetrachloride, chloroform, and bromotrichloro-methane: Role of cytochrome P-450. Life Sci. 1977; 20: 1541–1548
   PubMed Web of Science ®Google Scholar
• Pohl L. R., George J. W., Martin J. L., Krishna G. “Deuterium isotope effect in in vivo bioactivation of chloroform to phosgene”. Biochem. Pharmacol. 1979; 28: 561–563
   PubMed Web of Science ®Google Scholar
• Lavigne J. G., Marchand C. “The role of metabolism in chloroform hepatotoxicity”. Toxicol. Appl. Pharmacol. 1974; 29: 312–326
   PubMed Web of Science ®Google Scholar
• Klaassen C. D., Plaa G. L. Comparison of the biochemical alterations elicited in livers from rats treated with carbon tetrachloride, chloroform, 1,1, 2-trichloro-ethane, and 1,1,1-trichloroethane. Biochem. Pharmacol. 1969; 18: 2019–2027
   PubMed Web of Science ®Google Scholar
• Martz F., Straw J. A. Treatment with o. p'-DDD (Mitotane) decreased cytochrome P-450, heme, and microsomal protein content in the dog adrenal cortex in vivo. Res. Commun. Chem. Pathol. Pharmacol. 1976; 13: 83–92
   PubMedGoogle Scholar
• Reynolds E. S., Moslen M. T., Szabo S., Jaeger R. J. “Vinyl chloride-induced deactivation of cytochrome P-450 and other components of the liver mixed function oxidase system: An in vivo study”. Res. Commun. Chem. Pathol. Pharmacol. 1975; 12: 685–694
   PubMedGoogle Scholar
• Pessayre D., Allemand H., Wandscheer J. C., Descatoire V., Artigou J. Y., Benhamou J. P. Inhibition, activation, destruction, and induction of drug-metabolizing enzyme by trichloroethylene. Toxicol. Appl. Pharmacol. 1979; 49: 355–363
   PubMed Web of Science ®Google Scholar
• Guenge rich F. P., Strickland T. W. “Metabolism of vinyl chloride: Destruction of the heme of highly purified liver microsomal cytochrome P-450 by a metabolite”. Mol. Pharmacol. 1977; 13: 993–1004
   PubMed Web of Science ®Google Scholar
• Levin W., Jacobson M., Sernatinger E., Kuntzman R. “Breakdown of cytochrome P-450 heme by secobarbital and other allyl-containing barbiturates”. Drug Metab. Dispos. 1973; 1: 275–284
   PubMed Web of Science ®Google Scholar
• De Matteis F. “Drug-induced destruction of cytochrome P-450”. Drug Metab. Dispos. 1973; 1: 267–272
   PubMed Web of Science ®Google Scholar
• Loannides C., Parke D. V. “The effect of allyl compounds on hepatic microsomal mixed function oxidation and porphyrogenesis”. Chem.-Biol. Interact. 1976; 14: 241–249
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Mico B. A., Yost G. S., Correia M. A. Suicidal inactivation of cytochrome P-450: Covalent binding of allylisopropylacetamide to the heme prosthetic group. Enzyme-activated Irreversible Inhibitors, N. Seiler, M. J. Jung, L. Koch-Weser. Elsevier/North Holland, Amsterdam 1978; 337–352
   Google Scholar
• Ortiz de Montellano P. R., Yost G. S., Mico B. A., Dinizo S. E., Correia M. A., Kumbara H. “Destruction of cytochrome P-450 by 2-isopropyl-4-pentenamide and methyl 2-isopropyl-4-pentenoate: Mass speetrometric characterization of prosthetic heme adducts and nonparticipation of epoxide metabolites”. Arch. Biochem. Biophys 1979; 197: 524–533
   PubMedGoogle Scholar
• Ortiz de Montellano P. R., Mico B. A., Yost G. S. “Suicidal inactivation of cytochrome P-450: Formation of a heme-substrate covalent adduct”. Biochom. Biophys. Res. Commun. 1978; 83: 132–137
   PubMed Web of Science ®Google Scholar
• De Matteis F., Cantoni L. Alteration of the porphyrin nucleus of cytochrome P-450 caused in the liver by treatment with allyl-containing drugs: Is the modified porphyrin N-substituted?. Biochem. J. 1979; 83: 99–103
   Google Scholar
• Callot H. J., Schaeffer E. Model for the in vivo transformation of cytochrome P-450 into “green pigments,”. Tetrahedron Lett. 1980; 21: 1335–1338
   Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Mico B. A. “Destruction of cytochrome P-450 by ethylene and other olefins”. Mol. Pharmacol. 1980; 18: 128–135
   PubMed Web of Science ®Google Scholar
• Ivanetich K. M., Lucas S., Marsh J. A., Ziman M. R., Katz I. D., Bradshaw J. J. “Organic compounds: Their interaction with and degradation of hepatic microsomal drug-metabolizing enzymes in vitro”. Drug Metab. Dispos. 1978; 6: 218–225
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Kunze K. L. “Inactivation of hepatic cytochrome P-450 by allenic substrates”. Biochem. Biophys. Res. Commun. 1980; 94: 443–449
   PubMed Web of Science ®Google Scholar
• White I. N. H. “Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and haem”. Biochem. J. 1978; 174: 853–861
   PubMed Web of Science ®Google Scholar
• Sullivan H. R., Roffey P., McMahon R. E. Biotransformation of 4-ethynyl-2-fluorobiphenyl in the rat: In vitro and in vivo studies. Drug Metab. Dispos. 1979; 7: 76–80
   PubMed Web of Science ®Google Scholar
• Wade A., Symons A. W., Martin L., Parke D. V. “Metabolic oxidation of the ethynyl group in 4-ethynylbiphenyl”. Biochem. J. 1979; 184: 509–517
   PubMed Web of Science ®Google Scholar
• Wade A., Symons A. M., Martin L., Parke D. V. The metabolic oxidation of the ethynyl group in 4-ethynylbiphenyl in vitro. Biochem. J. 1980; 188: 867–872
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Kunze K. L., Yost G. S., Mico B. A. “Self-catalyzed destruction of cytochrome P-450: Covalent binding of ethynyl sterols to prosthetic heme”. Proc. Nat. Acad. Sci. U.S. 1979; 76: 746–749
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R., Kunze K. L. “Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates”. J. Biol. Chem. 1980; 255: 5578–5585
   PubMed Web of Science ®Google Scholar
• Kaul P. N., Kulkarni S. K. New drug metabolism inhibitor of marine origin. J. Pharni. Sci. 1978; 67: 1293–1296
   PubMed Web of Science ®Google Scholar
• Hanzlik R. P., Kishore V., Tullman R. “Cyclopropylamines as suicide substrates for cytochromes P-450”. J. Med. Chem. 1979; 22: 759–761
   PubMed Web of Science ®Google Scholar
• Neal R. A., Kamataki T., Hunter A. L., Catignani G. Monooxygenase catalyzed activation of thiono-sulfur containing compounds to reactive intermediates. 467–475, in Ref. 2
   Google Scholar
• Testa B., Jenner P. Drug Metabolism; Chemical and Biochemical Aspects. Marcel Dekker, New York 1976; 112–113
   Google Scholar
• Dalvi R. R., Neal R. A. “Metabolism in vivo of carbon disulfide to carbonyl sulfide and carbon dioxide in the rat”. Biochem. Pharmacol. 1978; 27: 1608–1609
   PubMed Web of Science ®Google Scholar
• Davis J. E., Mende T. J. “A study of the binding of sulfur to rat liver microsomes which occurs concurrently with the metabolism of O.O-diethyl O-p-nitrophenyl phosphorothionate (parathion) to O.O-diethyl O-p-nitrophenyl phosphate (para-oxon)”. J. Pharmacol. Exp. Ther. 1977; 201: 490–497
   PubMed Web of Science ®Google Scholar
• Kamataki T., Neal R. A. “Metabolism of diethyl p-nitro-phenyl phosphorothionate (parathion) by a reconstituted mixed-function oxidase enzyme system: Studies of covalent binding of the sulfur atom”. Mol. Pharmacol. 1976; 12: 933–944
   PubMed Web of Science ®Google Scholar
• Halpert J., Hammond D., Neal R. A. “Inactivation of purified rat liver cytochrome P-450 during the metabolism of parathion (diethyl p-nitrophenyl phosphorothionate)”. J. Biol. Chem. 1980; 255: 1080–1089
   PubMed Web of Science ®Google Scholar
• De Matteis F. “Covalent binding of sulfur to microsomes and loss of cytochrome P-450 during the oxidative desulfuration of several chemicals”. Mol. Pharmacol. 1974; 10: 849–854
   Web of Science ®Google Scholar
• Lee P. W., Neal R. A. “Metabolism of methimazole by rat liver cytochrome P-450-containing monooxygenases”. Drug Metab. Dispos. 1978; 6: 591–600
   PubMed Web of Science ®Google Scholar
• Järvisalo J., Savolainen H., Elovaara E. E., Vainio H. The in vivo toxicity of CS2 to liver microsomes: Binding of labelled CS2 and changes of the microsomal enzyme activities. Acta Pharmacol. Toxicol. 1977; 40: 329–336
   PubMedGoogle Scholar
• Jarvisalo J., Gibbs A. H., De Matteis F. “Accelerated conversion of heme to bile pigments caused in the liver by carbon disulfide and other sulfur-containing chemicals”. Mol. Pharmacol. 1978; 14: 1099–1106
   PubMed Web of Science ®Google Scholar
• Hunter A. L., Neal R. A. Inhibition of hepatic mixed-function oxidase activity in vitro and in vivo by various thiono-sulfur-containing compounds. Biochem. Pharmacol. 1975; 24: 2199–2205
   PubMed Web of Science ®Google Scholar
• Zemaitis M. A., Greene F. E. “In vivo and in vitro effects of thiuram disulfides and dithiocarbamates on hepatic microsomal drug metabolism in the rat”. Toxicol. Appl. Pharmacol. 1979; 48: 343–350
   PubMed Web of Science ®Google Scholar
• Freundt K. J. “Variable inhibition of human hepatic drug metabolizing enzymes by disulfiram”. Int. J. Clin. Pharmacol. Biopharm. 1978; 16: 323–330
   PubMedGoogle Scholar
• Svendsen T. L., Kristensen M. B., Hansen J. M., Skovsted L. “The influence of disulfiram on the half-life and metabolic clearance rate of diphenylhydantoin and tolbutamide in man”. Eur. J. Clin. Pharmacol. 1976; 9: 439–441
   Web of Science ®Google Scholar
• Marselos M., Alakuijala P., Lang M., Torronen R. Studies on the mechanism by which disulfiram and diethyldi-thiocarbamate affect drug metabolism. 589–596, in Ref. 2
   Google Scholar
• El-Hawari A. M., Plaa G. L. Impairment of hepatic mixed-function oxidase activity by α- and β-naphthylisothio-cyanate: Relationship to hepatotoxicity. Toxicol. Appl. Pharmacol. 1979; 48: 445–458
   PubMed Web of Science ®Google Scholar
• Menard R. H., Guenthner T. M., Taburet A. M., Kon H., Pohl L. R., Gillette J. R., Gelboin H. V., Trager W. F. “Specificity of the in vitro destruction of adrenal and hepatic microsomal steroid hydroxylases by thiosteroids”. Mol. Pharmacol. 1979; 16: 997–1010
   PubMed Web of Science ®Google Scholar
• Jeffery E., Kotake A., el Azhary R., Mannering G. J. Effects of linoleic acid hydroperoxide on the hepatic mono-oxygenase systems of microsomes from untreated, pheno-barbital-treated, and 3-methylcholanthrene-treated rats. Mol. Pharmacol. 1977; 13: 415–425
   PubMed Web of Science ®Google Scholar
• Jeffery E. H., Nerland D., el Azhary R., Mannering G. J. Destruction of cytochrome P-450 by linoleic acid hydroperoxide. 323–330, in Ref. 2
   Google Scholar
• Kato R., Iwasaki K., Shiraga T., Noguchi H. Evidence for the involvement of cytochrome P-450 in reduction of benzo[a]pyrene 4, 5-oxide by rat liver microsomes. Biochem. Biophys. Res. Comm. 1976; 70: 681–687
   PubMed Web of Science ®Google Scholar
• Patel J. M. “The destruction of pulmonary and hepatic cytochrome P-450 by phthalaldehyde”. Toxicol. Appl. Pharmacol. 1979; 48: 337–342
   PubMed Web of Science ®Google Scholar
• Reilly P. E. B., Ivey D. E. “Inhibition by chloramphenicol of the microsomal monooxygenase complex of rat liver”. FEBS Lett. 1979; 97: 141–146
   PubMed Web of Science ®Google Scholar
• Halpert J., Neal R. A. “Inactivation of purified rat liver cytochrome P-450 by chloramphenicol”. Mol. Pharmacol. 1980; 17: 427–431
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Nelson S. D., Krishna G. “Investigation of the mechanism of the metabolic activation of chloramphenicol by rat liver microsomes: Identification of a new metabolite”. Biochem. Pharmacol. 1978; 27: 491–496
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Reddy G. B., Krishna G. A new pathway of metabolism of chloramphenicol which influences the interpretation of its irreversible binding to protein in vivo. Biochem. Pharmacol. 1979; 28: 2433–2440
   PubMed Web of Science ®Google Scholar
• Thomas P. E., Lu A. Y. H., West S. B., Ryan D., Miwa G. T., Levin W. Accessibility of cytochrome P-450 in microsomal membranes: Inhibition of metabolism by antibodies to cytochrome P-450. Mol. Pharmacol. 1977; W: 819–831
   Google Scholar
• Kaminsky L. S., Fasco M. J., Guengerich F. P. “Comparison of different forms of purified cytochrome P-450 from rat liver by immunological inhibition of regio- and stereoselective metabolism of warfarin”. J. Biol. Chem. 1980; 255: 85–91
   PubMed Web of Science ®Google Scholar
• Maines M. D. The mechanism of degradation of endogenous heme and cytochrome P-450 by heme oxygenase. 543–550, in Ref. 2
   Google Scholar
• Eiseman J. L., Alvares A. P. “Alterations induced in heme pathway enzymes and monooxygenases by gold”. Mol. Pharmacol. 1978; 14: 1176–1188
   PubMed Web of Science ®Google Scholar
• Sasame H. A., Boyd M. R. “Paradoxical effects of co-baltous chloride and salts of other divalent metals on tissue levels of reduced glutathione and microsomal mixed-function oxidase components”. J. Pharmacol. Exp. Ther. 1978; 205: 718–724
   PubMed Web of Science ®Google Scholar
• Maines M. D. “Role of trace metals in regulation of cellular heme and hemoprotein metabolism: Sensitizing effects of chronic iron treatment on acute gold toxicity”. Drug Metab. Rev. 1979; 9: 237–255
   PubMed Web of Science ®Google Scholar
• Sinclair P., Gibbs A. H., Sinclair J. F., De Matteis F. “Formation of cobalt protoporphyrin in the liver of rats”. Bio-chem. J. 1979; 178: 529–538
   PubMed Web of Science ®Google Scholar
• Snell R. C., Yuhas E. M., Pence D. H., Means J. R., Roberts S. A., Yan E. T., Miya T. S., Mennear J. H. “Effect of acute and chronic cadmium treatment on hepatic drug metabolism in male rats”. Arch. Toxicol. 1978; 40: 269–277
   PubMed Web of Science ®Google Scholar
• Legrum W., Stuehmeier G., Netter K. J. “Cobalt as a modifier of microsomal monooxygenases in mice”. Toxicol. Appl. Pharmacol. 1979; 48: 195–204
   PubMed Web of Science ®Google Scholar
• Moldowan M. J., Behr K. “The effect of lead on amino-pyrine N-demethylation”. Res. Commun. Chem. Pathol. Pharmacol. 1979; 25: 343–355
   PubMedGoogle Scholar
• Alvares A. P., Kappas A. “Lead and polychlorinated bi-phenyls: Effects on heme and drug metabolism”. Drug Metab. Rev. 1979; 10: 91–106
   PubMed Web of Science ®Google Scholar
• Means J. R., Carlson G. P., Schnell R. C. Studies on the mechanism of cadmium-induced inhibition of the hepatic microsomal monooxygenase of the male rat. Toxicol. Appl. Pharmacol. 1979; 48: 293–304
   PubMed Web of Science ®Google Scholar
• Rosenberg D. W., Drummond G. S., Cornish H. C., Kappas A. “Prolonged induction of hepatic haem oxygenase and decreases in cytochrome P-450 content by organotin compounds”. Biochem. J. 1980; 190: 465–468
   PubMed Web of Science ®Google Scholar
• Kato R. “Effect of administration of 3-aminotriazole on the activity of microsomal drug-metabolizing enzyme systems of rat liver”. Jap. J. Pharmacol. 1967; 17: 56–63
   PubMedGoogle Scholar
• Belanger P. M., Grech-Belanger O., Labadie R. “Depression of hepatic microsomal enzyme system by amantadine hydrochloride in the rat”. J. Pharmacol. Exp. Ther. 1979; 211: 485–490
   PubMed Web of Science ®Google Scholar
• Renton K. W., Mannering G. J. “Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents”. Biochem. Biophys. Res. Commun. 1976; 73: 343–348
   PubMed Web of Science ®Google Scholar
• el Azhary R., Renton K. W., Mannering G. J. “Effect of interferon inducing agents (polyriboinosinic acid polyribocytidylic acid and tilorone) on the heme turnover of hepatic cytochrome P-450”. Mol. Pharmacol. 1980; 17: 395–399
   PubMed Web of Science ®Google Scholar
• Barnes D. W., Morahan P. S., Loveless S., Munson A. E. “The effects of maleic anhydride-divinyl ether (MVE) copolymers on hepatic microsomal mixed-function oxidases and other biologic activities”. J. Pharmacol. Exp. Ther. 1979; 208: 392–398
   PubMed Web of Science ®Google Scholar
• Gelboin H. V. Mechanisms of induction of drug metabolism enzymes, in Fundamental of Drug Metabolism and Drug Disposition, B. N. La Du, H. G. Mandel, E. L. Way. Williams & Wilkins, Baltimore 1972; 279–307
   Google Scholar
• Alvares A. P., Anderson K. E., Conney A. H., Kappas A. “Interactions between nutritional factors and drug biotransformations in man”. Proc. Nat. Acad. Sci. U.S. 1976; 73: 2501–2504
   PubMed Web of Science ®Google Scholar
• Paul C. J., Whitehouse L. W. “Metabolic basis for the supra-additive effect of the ethanol-diazepam combination in mice”. Brit. J. Pharmacol. 1977; 60: 83–90
   PubMed Web of Science ®Google Scholar
• Borowsky S. A., Lieber C. S. “Interaction of methadone and ethanol metabolism”. J. Pharmacol. Exp. Ther. 1978; 207: 123–129
   PubMed Web of Science ®Google Scholar
• Perrin L., Fabre J. “Implications cliniques des interactions medicamenteuses”. Schweiz. Rundschau Med. (Praxis) 1973; 62: 846–860
   PubMedGoogle Scholar
• Stockley I. Drug Interactions and Their Mechanisms. Pharmaceutical Press, London 1974
   Google Scholar
• Skovsted L., Hansen J. M., Kristensen H., Christensen L. K. Inhibition of drug metabolism in man. Drug Interactions, P. L. Morselli, S. Garattini, S. N. Cohen. Raven, New York 1974; 81–90
   Google Scholar
• Kutt H. “Interactions of antiepileptic drugs”. Epilepsia 1975; 16: 393–402
   PubMed Web of Science ®Google Scholar
• Kristensen M. B. “Drug interactions and clinical pharmacokinetics”. Clin. Pharmacol. 1976; 1: 351–372
   Google Scholar
• Egli M. Pharmakokinetik der Antiepileptika: Ihre Bedeutung fur die praktische Epilepsietherapie. Schweiz. Med. Wochenschr. 1977; 107: 1513–1524
   PubMedGoogle Scholar
• Greim H. An overview of the phenomenon of enzyme induction and inhibition: Their relevance to drug action and drug interactions. Concepts in Drug Metabolism, P. Jenner, B. Testa. Marcel Dekker, New York, in press. part B
   Google Scholar
• Rowland M., Matin J. B. “Kinetics of drug-drug interactions”. J. Pharmacokin. Biopharm. 1973; 1: 553–567
   Google Scholar
• Rowland M. Pharmacokinetics. Drug Metabolism; From Microbe to Man, D. V. Parke, R. L. Smith. Taylor and Francis, London 1977; 123–145
   Google Scholar
• Serlin M. J., Mossman S., Sibeon R. G., Brecken-Ridge A. M., Williams J. R. B., Atwood J. L., Willoughby J. M. T. “Cimetidine: Interaction with oral anticoagulants in man”. Lancet 1979; 2: 317–319
   PubMed Web of Science ®Google Scholar
• Klotz U., Anttila V. J., Reimann I. Cimetidine/diaze-pam interaction. Lancet 1979; 2: 699
   PubMed Web of Science ®Google Scholar
• Puurunen J., Sotaniemi E., Pelkonen O. “Effect of cimetidine on microsomal drug metabolism in man”. Eur. J. Clin. Pharmacol. 1980; 18: 185–188
   PubMed Web of Science ®Google Scholar
• Field B., Lu C., Hepner G. W. “Inhibition of hepatic drug metabolism by norethindrone”. Clin. Pharmacol. Ther. 1979; 25: 196–198
   PubMed Web of Science ®Google Scholar
• Faber O. K., Mouridsen H. T., Skovsted L. “The effect of chloramphenicol and sulfaphenazole on the biotransformation of cyclophosphamide in man”. Brit. J. Clin. Pharmacol. 1975; 2: 281–285
   PubMed Web of Science ®Google Scholar
• Lumholtz B., Siersbaek-Nielsen K., Skovsted L., Kamp-Mann J., Møtholm Hansen J. Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism. Clin. Pharmacol. Ther. 1975; 17: 731–734
   PubMed Web of Science ®Google Scholar
• Kristensen M. Medikament-medikament interaktion. Thesis, Foreningen of Danske Laegestuderendes Forlag, Copenhagen 1973
   Google Scholar
• Dubach U. C., Buckert A., Raaflaub J. “Einfluss von Sulfonamiden auf die blutzuckersenkcnde Wirkung oraler Antidiabetika”. Schweiz. Med. Wochenschr. 1966; 96: 1483–1487
   Google Scholar
• Kristensen M, Christensen L. K. Drug induced changes of the blood glucose lowering effect of oral hypoglycemic agents. Acta Diabetol. Lat., Suppl. 1969; 6(1)116–136
   PubMedGoogle Scholar
• Vessell E. S., Passananti G. T., Lee C. H. “Impairment of drug metabolism by disulfiram in man”. Clin. Pharmacol. Ther. 1971; 12: 785–792
   PubMed Web of Science ®Google Scholar
• Vessell E. S., Passananti G. T., Hepner G. W. “Interaction between antipyrine and aminopyrine”. Clin. Pharmacol. Ther. 1976; 20: 661–669
   PubMed Web of Science ®Google Scholar
• Richens A. “Drug estimation in the treatment of epilepsy”. Proc. Royal Soc. Med. 1974; 67: 1227–1229
   PubMedGoogle Scholar
• Ashley J. J., Levy G. “Inhibition of diphenylhydantoin elimination by its major metabolite”. Res. Commun. Chem. Path. Pharmacol. 1972; 4: 297–306
   PubMedGoogle Scholar
• Ashley J. J., Levy G. “Kinetics of diphenylhydantoin metabolism in rats”. J. Pharmacokin. Biopharm. 1973; 1: 99–102
   PubMedGoogle Scholar
• Christensen L. K., Skovsted L. “Inhibition of drug metabolism by chloramphenicol”. Lancet 1969; 2: 1397–1399
   PubMed Web of Science ®Google Scholar
• Solomon H. M, Schrogie J. J. “The effect of phenyrami-dol on the metabolism of bishydroxycoumarin”. J. Pharmacol. Exp. Ther. 1964; 154: 660–666
   Web of Science ®Google Scholar
• Eade N. R., Renton K. W. “Effect of monoamine oxidase inhibitors on the N-demethylation and hydrolysis of meperidine”. Biochem. Pharmacol. 1970; 19: 2243–2250
   PubMed Web of Science ®Google Scholar
• Goldstein M., Nelson E. B. “Metyrapone as a treatment for acetaminophen (paracetamol) toxicity in mice”. Res. Commun. Chem. Path. Pharmacol. 1979; 23: 203–206
   PubMedGoogle Scholar
• Fossa A. A., Hadley W. M., Born J. L. Decrease in acetaminophen toxicity in mice treated with metyrapone. Toxicol. Lett. 1979; 4: 379–384
   Web of Science ®Google Scholar
• Siegers C. P., Younes M. “Einfluss von 2-Dimethyl-aminoethanol auf die hepatotoxischen Wirkungen von Paracetamol bei Ratten und Mausen”. Arzneim. -Forsch. 1979; 29: 520–523
   PubMedGoogle Scholar
• Mitchell J. R., Jollow D. J., Potter W. Z., Davis D. C., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis, I: Role of drug metabolism. J. Pharmacol. Exp. Ther. 1973; 187: 185–194
   PubMed Web of Science ®Google Scholar